Joe Thomas
Plus aucun poste en cours
Profil
Joe Thomas served as an Independent Non-Executive Director at Everonn Education Ltd.
from 2011 to 2012.
He then worked as the Chief Operating Officer & Managing Director at Bioserve Biotechnologies (India) Pvt Ltd.
from 2012 to 2014.
Later, he served as an Independent Director at Outlook Therapeutics, Inc. from 2017 to 2019.
He also worked as a Director at Stelis Biopharma Ltd.
and Tenshi Healthcare Pte Ltd.
Additionally, he served as the Chief Corporate Development Officer at Strides Pharma Science Ltd.
from 2012 to 2015.
Mr. Thomas completed his undergraduate and graduate degrees from the University of Delhi.
Anciens postes connus de Joe Thomas
| Sociétés | Poste | Fin |
|---|---|---|
| OUTLOOK THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/12/2019 |
| STRIDES PHARMA SCIENCE LIMITED | Corporate Officer/Principal | 01/03/2015 |
| EVERONN EDUCATION LTD | Directeur/Membre du Conseil | 25/09/2012 |
Tenshi Healthcare Pte Ltd.
 Tenshi Healthcare Pte Ltd. Financial ConglomeratesFinance Tenshi Healthcare Pte Ltd. is the Singaporean parent company of Biolexis Therapeutics, a clinical-stage biopharmaceutical company that develops small molecules targeting various diseases, including cancers, immune-mediated, neurodegenerative, auto-immune, metabolic, and inflammatory diseases. The private company is based in Singapore, Singapore. Biolexis uses a proprietary molecular AI-enabled drug discovery process to rapidly discover and develop novel clinical candidates. The company is also focused on building and in-licensing a portfolio of advanced biosimilars, peptides, and vaccines with a high focus on quality, affordability, and accessibility. Biolexis has a proprietary platform technology to develop and commercialize recombinant insulin and insulin analogs with high purity and consistent quality. | Directeur/Membre du Conseil | - |
Stelis Biopharma Ltd.
 Stelis Biopharma Ltd. Pharmaceuticals: MajorHealth Technology Stelis Biopharma Pvt Ltd. develops and manufactures pharmaceutical products. The company was founded in 2007 and is headquartered in Bangalore, India. | Directeur/Membre du Conseil | - |
Formation de Joe Thomas
| University of Delhi | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| STRIDES PHARMA SCIENCE LIMITED | Health Technology |
| OUTLOOK THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Everonn Education Ltd.
 Everonn Education Ltd. Miscellaneous Commercial ServicesCommercial Services Everonn Education Ltd. engaged in the provision of education and training services. It offered instructional and computer technology services in various state government schools and bodies, through long term contracts. The company was founded by Padmanabhan Kishore and Susha John on April 19, 2000 and is headquartered in Chennai, India. | Commercial Services |
Bioserve Biotechnologies (India) Pvt Ltd.
 Bioserve Biotechnologies (India) Pvt Ltd. Drugstore ChainsRetail Trade Bioserve Biotechnologies (India) Pvt Ltd. engages in the provision of genomic products and services. The company was founded on February 21, 1994 and is headquartered in Hyderabad, India. | Retail Trade |
Stelis Biopharma Ltd.
Stelis Biopharma Ltd. Pharmaceuticals: MajorHealth Technology Stelis Biopharma Pvt Ltd. develops and manufactures pharmaceutical products. The company was founded in 2007 and is headquartered in Bangalore, India. | Health Technology |
Tenshi Healthcare Pte Ltd.
Tenshi Healthcare Pte Ltd. Financial ConglomeratesFinance Tenshi Healthcare Pte Ltd. is the Singaporean parent company of Biolexis Therapeutics, a clinical-stage biopharmaceutical company that develops small molecules targeting various diseases, including cancers, immune-mediated, neurodegenerative, auto-immune, metabolic, and inflammatory diseases. The private company is based in Singapore, Singapore. Biolexis uses a proprietary molecular AI-enabled drug discovery process to rapidly discover and develop novel clinical candidates. The company is also focused on building and in-licensing a portfolio of advanced biosimilars, peptides, and vaccines with a high focus on quality, affordability, and accessibility. Biolexis has a proprietary platform technology to develop and commercialize recombinant insulin and insulin analogs with high purity and consistent quality. | Finance |
